Once was enough
Realizing it may have caught lightning in a bottle with its licensing arrangement for Roche's CellCept, Aspreva Pharmaceuticals Corp. gave up its search for new in-licensing candidates and instead agreed to sell itself to Galenica Group. The Swiss company, in turn, needed a North American presence as it awaits an FDA response on an NDA for its Ferinject iron replacement.
Aspreva (TSX:ASV; ASPV, Victoria, B.C.) began life by scouring big pharma's shelves for marketed products with potential in peripheral indications,